Literature DB >> 10230691

HLA-DR expression is a significant prognostic factor in laryngeal cancer. A morphometric study.

B Sikorska1, M Danilewicz, M Wagrowska-Danilewicz.   

Abstract

HLA-DR antigen expression in tumour cells was investigated in 68 laryngeal carcinomas. The tissue sections were studied by a morphometric method using a computer image analysis system. Although the highest number of HLA-DR-positive cells was observed in the groups with the lowest clinical stage, these differences did not reach statistical significance. Analysis of survival showed a significantly different survival time of patients classified as HLA-DR positive (10% and more HLA-DR+tumour cells) compared to those classified as HLA-DR negative. There were no significant differences in survival times between patients with glottic and extraglottic cancers, or between patients with various grades of histological malignancy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10230691     DOI: 10.1111/j.1699-0463.1999.tb01569.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  5 in total

1.  Role of dendritic cells in progression and clinical outcome of colon cancer.

Authors:  Maya V Gulubova; Julian R Ananiev; Tatyana I Vlaykova; Yovcho Yovchev; Vanya Tsoneva; Irena M Manolova
Journal:  Int J Colorectal Dis       Date:  2011-11-09       Impact factor: 2.571

2.  Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin's gastric lymphoma patients.

Authors:  Alexander Darom; Ilias P Gomatos; Emmanuel Leandros; Emmu Chatzigianni; Dimitris Panousopoulos; Manousos M Konstadoulakis; George Androulakis
Journal:  World J Gastroenterol       Date:  2006-03-28       Impact factor: 5.742

3.  Assessment of Human Leukocyte Antigen Differences between Smokers with Reinke's Edema and Those with Laryngeal Cancer.

Authors:  Farzad Izadi; Aslan Ahmadi; Farideh Hosseinzadeh; Marjan Mirsalehi; Yadollah Shakiba; Mohammad Ali Bahar; Maryam Balali
Journal:  Iran J Otorhinolaryngol       Date:  2022-03

4.  HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients.

Authors:  Christian M Tegeler; Jonas Scheid; Hans-Georg Rammensee; Helmut R Salih; Juliane S Walz; Jonas S Heitmann; Annika Nelde
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

5.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.